Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Sep 12;2012(9):CD008714.
doi: 10.1002/14651858.CD008714.pub2.

Chlorambucil for patients with primary biliary cirrhosis

Wei Xin Li  1 , Xiang Yan, Chun Rui Shi, Ai Ping Zhang
Affiliations

Chlorambucil for patients with primary biliary cirrhosis

Wei Xin Li et al. Cochrane Database Syst Rev. .

Abstract

Background: Chlorambucil has been used for patients with primary biliary cirrhosis as it possesses immunosuppressive properties. But it is unknown whether it benefits or harms these patients.

Objectives: To evaluate the beneficial and any harmful effects of chlorambucil for primary biliary cirrhosis patients.

Search methods: Eligible trials were identified by searching the Cochrane Hepato-Biliary Group Controlled Trials Register (March 2012), the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (2012, Issue 2), MEDLINE (1946 to March 2012), EMBASE (1974 to March 2012), Science Citation Index EXPANDED (1900 to March 2012), The Chinese Biomedical Database (1976 to March 2012), The Chinese Medical Current Contents (1994 to March 2012), The China Hospital Knowledge Database (1994 to March 2012), and a database of ongoing trials (http://www.controlled-trials.com/mrct/) (accessed 6 March 2012). The reference lists of the retrieved publications and review articles were also read through, and pharmaceutical companies known to produce chlorambucil were contacted.

Selection criteria: Randomised clinical trials, irrespective of language, year of publication, and publication status, comparing chlorambucil at any dose versus placebo, no intervention, another active drug, or one dose of chlorambucil with another dose.

Data collection and analysis: We planned to assess continuous data with mean differences (MD), and dichotomous outcomes with relative risk (RR), both with 95% confidence intervals (CI). As we only identified one trial, Fisher's exact tests were employed.

Main results: Only one randomised trial was identified and included in the review. The bias risk in the trial was high. The trial compared chlorambucil versus no intervention in 24 patients with primary biliary cirrhosis. Fisher's exact test did not show a significant reduction of mortality when comparing chlorambucil with no treatment (0/13 (0%) versus (2/11 (18.2%); P = 0.20). There was no significant difference regarding adverse events for chlorambucil compared with no treatment, but all patients receiving chlorambucil experienced adverse events (13/13 (100%) versus (3/11 (27%); P = 0.1). According to the authors of the trial, chlorambucil led to a significant improvement in mean serum levels of bilirubin (P < 0.05), albumin (P < 0.05), immunoglobulin M (P < 0.01), serum aspartate aminotransferase activity (P < 0.01), and hepatic inflammatory infiltrates (P < 0.01).

Authors' conclusions: There is not sufficient evidence to support or reject the use of chlorambucil for patients with primary biliary cirrhosis. Chlorambucil may show benefit in some unvalidated surrogate outcome measures (for example, serum bilirubin and immunoglobulin M levels). Chlorambucil is, however, connected with a number of adverse events. Bone marrow suppression should be noted in particular. Further randomised clinical trials are necessary to assess the benefits and harms of chlorambucil in this indication.

PubMed Disclaimer

Conflict of interest statement

None known

Figures

1
1
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD008714

References

References to studies included in this review

Hoofnagle 1986 {published data only}
    1. Hoofnagle JH, Davis GL, Schafer DF, Peters M, Avigan MI, Pappas SC, et al. Randomized trial of chlorambucil for primary biliary cirrhosis. Gastroenterology 1986;91(6):1327‐34. - PubMed
    1. Hoofnagle JH, Davis GL, Schafer DF, Peters MG, Avigan MI, Hanson RG, et al. Randomized trial of chlorambucil for primary biliary cirrhosis [AASLD abstract]. Hepatology 1984;4(5):1062. - PubMed

References to studies excluded from this review

Kaplan 1987 {published data only}
    1. Kaplan MM. Another treatment for primary biliary cirrhosis. Gastroenterology 1987;92(1):255‐7. - PubMed

Additional references

Alempijevic 2009
    1. Alempijevic T, Krstic M, Jesic R, Jovanovic I, Sokic Milutinovic A, Kovacevic N, et al. Biochemical markers for non‐invasive assessment of disease stage in patients with primary biliary cirrhosis. World Journal of Gastroenterology 2009;15(5):591‐4. - PMC - PubMed
Baker 2003
    1. Baker SG, Kramer BS. A perfect correlate does not a surrogate make. BMC Medical Research Methodology 2003;3:16. - PMC - PubMed
Bergasa 2005
    1. Bergasa NV. The pruritus of cholestasis. Journal of Hepatology 2005;43(6):1078‐88. - PubMed
Cannon 1985
    1. Cannon GW, Jackson CG, Samuelson CO Jr, Ward JR, Williams HJ, Clegg DO. Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review. Seminars in Arthritis and Rheumatism 1985;15(2):106‐18. - PubMed
Chisesi 1991
    1. Chisesi T, Congiu M, Contu A, Coser P, Moretti L, Porcellini A, et al. Randomized study of chlorambucil (CB) compared to interferon (alfa‐2b) combined with CB in low‐grade non‐Hodgkin's lymphoma: an interim report of a randomized study. Non‐Hodgkin's Lymphoma Cooperative Study Group. European Journal of Cancer 1991;Suppl 4:31‐3. - PubMed
Christensen 1985
    1. Christensen E, Neuberger J, Crowe J, Altman DG, Popper H, Portmann B, et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology 1985;89(5):1084‐91. - PubMed
Clements 1993
    1. Clements P, Lachenbruch P, Furst D, Paulus H. The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. Arthritis and Rheumatism 1993;36(11):1575‐9. - PubMed
Dickson 1985
    1. Dickson ER, Fleming TR, Wiesner RH, Baldus WP, Fleming CR, Ludwig J, et al. Trial of penicillamine in advanced primary biliary cirrhosis. New England Journal of Medicine 1985;312(16):1011‐5. - PubMed
Dickson 1989
    1. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10(1):1‐7. - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315(7109):629‐34. - PMC - PubMed
Gershwin 1987
    1. Gershwin ME, Mackay IR, Sturgess A, Coppel RL. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. Journal of Immunology 1987;138(10):3525‐31. - PubMed
Gershwin 2008
    1. Gershwin ME, Mackay IR. The causes of primary biliary cirrhosis: Convenient and inconvenient truths. Hepatology 2008;47(2):737‐45. - PubMed
Giljaca 2010
    1. Giljaca V, Poropat G, StimacD, Gluud C. Methotrexate for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD004385.pub3] - DOI - PubMed
Gluud 2005
    1. Gluud C. Mortality from cirrhosis: lack of progress over the last 35 years. Gut 2005;54(11):1523‐6. - PMC - PubMed
Gluud 2012
    1. Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als‐Nielsen B, Colli A, et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2012, Issue 2. Art. No.: LIVER.
Goldblatt 2002
    1. Goldblatt J, Taylor PJ, Lipman T, Prince MI, Baragiotta A, Bassendine MF, et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 2002;122(5):1235‐41. - PubMed
Gong 2004a
    1. Gong Y, Klingenberg SL, Gluud C. D‐penicillamine for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD004789.pub2] - DOI - PMC - PubMed
Gong 2004b
    1. Gong Y, Gluud C. Colchicine for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2004, Issue 2. [DOI: 10.1002/14651858.CD004481.pub2] - DOI - PubMed
Gong 2007a
    1. Gong Y, Christensen E, Gluud C. Cyclosporin A for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD005526.pub2] - DOI - PMC - PubMed
Gong 2007b
    1. Gong Y, Christensen E, Gluud C. Azathioprine for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006000.pub2] - DOI - PMC - PubMed
Gong 2008
    1. Gong Y, Huang ZB, Christensen E, Gluud C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD000551.pub2] - DOI - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hoofnagle 1984
    1. Hoofnagle JH, Davis GL, Schafer DF, Peters MG, Avigan MI, Hanson RG, et al. Randomized trial of chlorambucil for primary biliary cirrhosis [AASLD abstract]. Hepatology 1984;4(5):1062. - PubMed
Hughes 1983
    1. Hughes GS Jr, Kataria YP, O'Brien TF Jr. Sarcoidosis presenting as biliary cirrhosis: treatment with chlorambucil. Southern Medical Journal 1983;76(11):1440‐2. - PubMed
ICH‐GCP 1997
    1. International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice 1997 CFR & ICH Guidelines. Vol. 1, PA 19063‐2043, USA: Barnett International/PAREXEL, 1997.
Invernizzi 1997
    1. Invernizzi P, Crosignani A, Battezzati PM, Covini G, Valle G, Larghi A, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody‐positive and ‐negative primary biliary cirrhosis. Hepatology 1997;25(5):1090‐5. - PubMed
Ishibashi 2011
    1. Ishibashi H, Komori A, Shimoda S, Ambrosini YM, Gershwin ME, Nakamura M. Risk factors and prediction of long‐term outcome in primary biliary cirrhosis. Internal Medicine 2011;50(1):1‐10. - PubMed
Israel 1991
    1. Israel HL, McComb BL. Chlorambucil treatment of sarcoidosis. Sarcoidosis 1991;8(1):35‐41. - PubMed
Johnson 2005
    1. Johnson SA, Owen RG, Oscier DG, Leblond V, Levy V, Jaeger U, et al. Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders. Clinical Lymphoma 2005;5(4):294‐7. - PubMed
Kaplan 1991
    1. Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low‐dose weekly methotrexate. Gastroenterology 1991;101(5):1332‐8. - PubMed
Kaplan 1997
    1. Kaplan MM. The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis. Seminars in Liver Disease 1997;17(2):129‐36. - PubMed
Kaplan 2002
    1. Kaplan MM. Primary biliary cirrhosis: past, present, and future. Gastroenterology 2002;123(4):1392‐4. - PubMed
Kaplan 2005
    1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. New England Journal of Medicine 2005;353(12):1261‐73. - PubMed
Keus 2009
    1. Keus F, Wetterslev J, Gluud C, Gooszen HG, Laarhoven CJ. Robustness assessments are needed to reduce bias in meta‐analyses that include zero‐event randomized trials. American Journal of Gastroenterology 2009;104(3):546‐51. - PubMed
Kim 2002
    1. Kim WR, Brown RS Jr, Terrault NA, El‐Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002;36(1):227‐42. - PubMed
Kjaergard 2001
    1. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135(11):982‐9. - PubMed
Knauf 2009
    1. Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. Journal of Clinical Oncology 2009;27(26):4378‐84. - PubMed
Kyle 2000
    1. Kyle RA, Greipp PR, Gertz MA, Witzig TE, Lust JA, Lacy MQ, et al. Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. British Journal of Haematology 2000;108(4):737‐42. - PubMed
Lindor 2009
    1. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology 2009;50(1):291‐308. - PubMed
Miller 1997
    1. Miller E. The use of cytotoxic agents in the treatment of immune‐mediated diseases of dogs and cats. Seminars in Veterinary Medicine and Surgery (small animal) 1997;12(3):157‐60. - PubMed
Mitchison 1992
    1. Mitchison HC, Palmer JM, Bassendine MF, Watson AJ, Record CO, James OF. A controlled trial of prednisolone treatment in primary biliary cirrhosis. Three‐year results. Journal of Hepatology 1992;15(3):336‐44. - PubMed
Moher 1998
    1. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352(9128):609‐13. - PubMed
Nand 1997
    1. Nand N, Das R, Jaswal TS. Evaluation of efficacy of methylprednisolone, prednisolone and chlorambucil in idiopathic glomerulonephritis. Journal of the Indian Medical Association 1997;95(6):163‐5, 174. - PubMed
Neuberger 1985
    1. Neuberger J, Christensen E, Portmann B, Caballeria J, Rodes J, Ranek L, et al. Double blind controlled trial of d‐penicillamine in patients with primary biliary cirrhosis. Gut 1985;26(2):114‐9. - PMC - PubMed
Niaudet 1992
    1. Niaudet P. Comparison of cyclosporin and chlorambucil in the treatment of steroid‐dependent idiopathic nephrotic syndrome: a multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatric Nephrology 1992;6(1):1‐3. - PubMed
Pasha 1997
    1. Pasha TM, Dickson ER. Survival algorithms and outcome analysis in primary biliary cirrhosis. Seminars in Liver Disease 1997;17(2):147‐58. - PubMed
Ponticelli 1995
    1. Ponticelli C, Zucchelli P, Passerini P, Cesana B, Locatelli F, Pasquali S, et al. A 10‐year follow‐up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy. Kidney International 1995;48(5):1600‐4. - PubMed
Poupon 1996
    1. Poupon RE, Huet PM, Poupon R, Bonnand AM, Nhieu JT, Zafrani ES. A randomized trial comparing colchicine and ursodeoxycholic acid combination to ursodeoxycholic acid in primary biliary cirrhosis. UDCA‐PBC Study Group. Hepatology 1996;24(5):1098‐103. - PubMed
Prince 2004
    1. Prince MI, Chetwynd A, Craig WL, Metcalf JV, James OF. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004;53(6):865‐70. - PMC - PubMed
Prince 2005
    1. Prince M, Christensen E, Gluud C. Glucocorticosteroids for primary biliary cirrhosis. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD003778.pub2] - DOI - PMC - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Robak 2000
    1. Robak T, Bloński JZ, Kasznicki M, Blasińska‐Morawiec M, Krykowski E, Dmoszyńska A, et al. Cladribine with prednisone versus chlorambucil with prednisone as first‐line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 2000;96(8):2723‐9. - PubMed
Royle 2003
    1. Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591‐603. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12. - PubMed
Senn 1997
    1. Senn HJ, Maibach R, Castiglione M, Jungi WF, Cavalli F, Leyvraz S, et al. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil ‐ 11‐year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82. Journal of Clinical Oncology 1997;15(7):2502‐9. - PubMed
Sood 2004
    1. Sood S, Gow PJ, Christie JM, Angus PW. Epidemiology of primary biliary cirrhosis in Victoria, Australia: High prevalence in migrant populations. Gastroenterology 2004;127(2):470‐5. - PubMed
Tattersall 1992
    1. Tattersall MH, Swanson CE, Solomon HJ. Long‐term survival with advanced ovarian cancer: an analysis of 5‐year survivors in the Australian trial comparing combination versus sequential chlorambucil and cisplatin therapy. Gynecologic Oncology 1992;47(3):292‐7. - PubMed
Taylor 2006
    1. Taylor PR, White JM, Prescott RJ, Angus B, Galloway MJ, Jackson GH, et al. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non‐Hodgkin's lymphoma: Results of the Scotlandand Newcastle Lymphoma Group randomized NHL VIII trial. Leukemia & Lymphoma 2006;47(11):2321‐30. - PubMed
Verma 1999
    1. Verma A, Jazrawi RP, Ahmed HA, Northfield TC. Prescribing habits in primary biliary cirrhosis: a national survey. European Journal of Gastroenterology & Hepatology 1999;11(8):817‐20. - PubMed
Wiesner 1990
    1. Wiesner RH, Ludwig J, Lindor KD, Jorgensen RA, Baldus WP, Homburger HA, et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. New England Journal of Medicine 1990;322(20):1419‐24. - PubMed
Wood 2008
    1. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601‐5. - PMC - PubMed

Publication types

MeSH terms